1.In vitro activities of meropenem, imipenem and ofloxacin against aerobic gram-negative bacilli and gram-positive cocci.
Yunsop CHONG ; Kyungwon LEE ; Samuel Y LEE
Korean Journal of Infectious Diseases 1991;23(2):95-105
No abstract available.
Gram-Positive Cocci*
;
Imipenem*
;
Ofloxacin*
2.In vitro Susceptibility of Imipenem-resistant Pseudomonas aeruginosa against Piperacillin/tazobactam.
Korean Journal of Clinical Microbiology 2007;10(2):171-172
Minimal inhibitory concentrations (MICs) against piperacillin/tazobactam were determined on a total of 50 clinical isolates of imipenem resistant Pseudomonas aeruginosa (IRPA). MIC50 and MIC90 were 32microgram/mL and 512microgram/mL, respectively. The susceptibility of IRPA against piperacillin/tazobactam was 59%. Of the 50 IRPA strains, only two were PCR positive for blaVIM and none for blaIMP.
Imipenem
;
Polymerase Chain Reaction
;
Pseudomonas aeruginosa*
;
Pseudomonas*
3.Abrupt Increase in Rate of Imipenem Resistance in Acinetobacter baumannii Complex Strains Isolated from General Hospitals in Korea and Correlation With Carbapenem Administration During 2002–2013.
Young Ah KIM ; Yoon Soo PARK ; Taemi YOUK ; Hyukmin LEE ; Kyungwon LEE
Annals of Laboratory Medicine 2018;38(2):179-181
No abstract available.
Acinetobacter baumannii*
;
Acinetobacter*
;
Hospitals, General*
;
Imipenem*
;
Korea*
4.Evaluation of Methods for Detection of Antimicrobial Resistance of Acinetobacter baumannii to Imipenem.
The Korean Journal of Laboratory Medicine 2003;23(6):388-394
BACKGROUND: In our hospital, an abrupt increase in the resistant rate of A. baumannii to imipenem was observed. We evaluated the imipenem minimal inhibitory concentration (MIC) of an automated system that our laboratory is using, by comparing with those of other methods. METHODS: During the period from February 2002 to February 2003, the imipenem MICs of the agar dilution method, Etest(R), and the disk diffusion method, were compared for imipenem-resistant A. baumannii tested by an automated system in 46 samples at Chung-Ang University Phil-Dong Hospital. We tested for susceptibility to imipenem with the Vitek system by using the GNI card, the disk diffusion method by using the imipenem disk (BBL(TM)), and the agar dilution method. PCR testing of the isolates for carbapenemase genes (IMP-1 and VIM-2) detected in other hospitals was done using published primers and conditions. RESULTS: By the agar dilution method, 23 (50.0%) isolates were susceptible to imipenem, 14 (30.4%) isolates were intermediate, and 9 (19.6%) isolates were resistant. However, by the Etest, 8 (17.4%) were susceptible to imipenem, and 28 (60.9%) isolates were resistant. By the disk diffusion method, the susceptible isolates were 14 (30.4%) and the resistant isolates were 17 (37.0%). Quantitative agreement between the agar dilution method and the disk diffusion test gave an inverse linear correlation coefficient (r=-0.564). The results of the 13 isolates, whose results of the MIC were below 2 or above 16 in the agar dilution method, corresponded with the Etest and the disk diffusion test. The IMP-1 gene was detected in one isolate. CONCLUSIONS: It is recommended that when a gram-negative bacilli isolate including A. baumannii is characterized as resistant to imipenem by the Vitek system, an additional simple test, such as the disk diffusion assay, might be used.
Acinetobacter baumannii*
;
Agar
;
Diffusion
;
Imipenem*
;
Polymerase Chain Reaction
5.In vitro Comparison of Anti-Biofilm Effects against Carbapenem-Resistant Acinetobacter baumannii: Imipenem, Colistin, Tigecycline, Rifampicin and Combinations.
Joon Young SONG ; Hee Jin CHEONG ; Ji Yun NOH ; Woo Joo KIM
Infection and Chemotherapy 2015;47(1):27-32
BACKGROUND: Multi-drug resistant (MDR) Acinetobacter baumannii has emerged as one of the most important nosocomial pathogens. In addition to the diverse resistance mechanisms, some A. baumannii strains are known to have biofilm-producing capacity, thereby decreasing antibiotic effectiveness. MATERIALS AND METHODS: This study was designed to assess biofilm-producing capacity of three different MDR A. baumannii strains with diverse resistance mechanisms (OXA-51, IMP-1 and VIM-2 type beta-lactamases), and intended to compare the effect of each antibiotic regimen (rifampicin, colistin, imipenem, tigecycline, rifampicin-imipenem and rifampicin-colistin) on mature A. baumannii biofilms using in vitro polystyrene plate biofilm assay. RESULTS: Among three MDR A. baumannii strains, only VIM-2 strain produced strong biofilm compared to the controls (optical density, 8.04 +/- 2.16 vs. 0.49 +/- 0.26). Regarding VIM-2 strains, none of imipenem, colistin and rifampicin reduced biofilm formation alone at MIC of each antibiotic agent (inhibition of biofilm synthesis, less than 30%). In comparison, tigecyclin (0.76 +/- 0.23), imipenem-rifampicin (1.07 +/- 0.31) and colistin-rifampicin (1.47 +/- 0.54) showed a significant inhibition of biofilm synthesis compared to the positive controls at 48 hours after incubation (P<0.01). Tigecycline inhibited biofilm formation even at the one fourth level of MIC (1.17 +/- 0.21). Likewise, both imipenem and colistin were also effective even with the reduced concentrations when those were combined with rifampicin. Such biofilm-inhibiting effects with those antibiotic regimens sustained up to 96 hours after incubation. CONCLUSION: Tigecycline, imipenem-rifampicin and colistin-rifampicin would be effective for the prevention or reduction of biofilm formation caused by A. baumannii strains.
Acinetobacter baumannii*
;
Anti-Bacterial Agents
;
Biofilms
;
Colistin*
;
Imipenem*
;
Polystyrenes
;
Rifampin*
6.In Vitro Activity of Antimicrobial Combination against Multidrug-resistant Strains of Acinetobacter baumannii.
The Korean Journal of Laboratory Medicine 2005;25(5):312-316
BACKGROUND: Acinetobacter baumannii has been reported as a major cause of nosocomial infections with increasing frequency. Recently, the emergence of carbapenem-resistant strains has become a major problem in treatment. The use of nontraditional agents such as colistin and a combination therapy have been tried. The purpose of this study was to evaluate the activity of antimicrobial combinations against multidrug-resistant (MDR) A. baumannii. METHODS: Twenty-nine strains of MDR A. baumannii, either resistant or intermediate to imipenem, were collected from February 2003 to February 2004. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. The checkerboard method was used to assess the activity of ampicillin-sulbactam in combination with amikacin, tobramycin or meropenem and colistin in combination with ceftazidime, meropenem, or rifampin. RESULTS: The MIC90 of ceftazidime and cefepime were 2, 048 g/mL and 512 g/mL, respectively, while the MIC90 of colistin was 0.5 g/mL. The antimicrobial combinations that showed an additive effect for one or two strains were colistin with rifampin or ceftazidime and ampicillin-sulbactam with tobramycin or meropenem. Other antimicrobial combinations showed indifferent effects against most strains. There were no synergistic or antagonistic combinations. CONCLUSIONS: These data suggested that colistin may be an alternative drug for MDR A. baumannii. For the effective treatment of patients infected with these resistant strains, further studies are needed to evaluate antimicrobial combinations against a large number of heterogeneous isolates, and these studies must be followed by clinical trials.
Acinetobacter baumannii*
;
Agar
;
Amikacin
;
Ceftazidime
;
Colistin
;
Cross Infection
;
Humans
;
Imipenem
;
Microbial Sensitivity Tests
;
Rifampin
;
Tobramycin
7.Carbapenem-Resistant Acinetobacter baumannii.
Il Kwon BAE ; Seok Hoon JEONG ; Kyungwon LEE
Korean Journal of Clinical Microbiology 2012;15(1):1-8
Clinical isolates of Acinetobacter spp. in Korea exhibit higher antimicrobial resistance rates than in foreign countries and frequently show multi-drug resistance. Approximately 67% (272/405) of Acinetobacter baumannii isolates collected from 19 hospitals in Korea in 2008 exhibited intermediate susceptibility or resistance to imipenem and/or meropenem. The most important mechanisms in acquiring carbapenem resistance in A. baumannii in Korea are production of OXA-23 and overproduction of OXA-51, while that in non-baumannii Acinetobacter is the production of metallo-beta-lactamases. All the carbapenem-resistant A. baumannii isolates were identified as clonal complex 92 and belonged to worldwide clone 2.
Acinetobacter
;
Acinetobacter baumannii
;
Clone Cells
;
Drug Resistance, Multiple
;
Imipenem
;
Korea
;
Thienamycins
8.False Susceptibility to Imipenem by Vitek GPS Card in Enterococcus faecium.
Hae Kyung LEE ; Yeon Joon PARK ; Hi Jeong KWON ; Eun Jung LEE ; Byung Kee KIM ; Chang Suk KANG
Journal of Laboratory Medicine and Quality Assurance 2003;25(2):211-214
BACKGROUND: Enterococcus faecium (E. faecium) is potential pathogens of mixed infections for which a broad-spectrum antimicrobial agents such as imipenem has a therapeutic role. But controversy continues concerning testing imipenem versus enterococci. The purpose of this study were 1) to investigate the ability of penicillin and ampicillin minimum inhibitory concentration (MIC) to predict in vitro susceptibility of E. faecium versus imipenem. and 2) to compare MICs of ampicillin, penicillin and imipenem by the Vitek system with those by agar dilution method. METHODS: Fifty-two isolates of E. faecium between April 2002 and May 2002 were tested. Each isolate was tested versus penicillin, ampicillin and imipenem. MICs were determined by Vitek system and agar dilution method according to NCCLS guidelines. Imipenem MIC determinations were repeated by E-test. RESULTS: MIC of Vitek system tends to be lower than that of agar dilution method, but there was good concordance between MICs of penicillin and ampicillin by Vitek system and agar dilution method. But for imipenem, the MICs by the agar dilution method did not correspond with the Vitek results. Of the 52 E. faecium isolates tested, in vitro activity of penicillin and ampicillin accurately predicts that of imipenem. CONCLUSIONS: MICs of ampicillin and penicillin are reliable, but imipenem MIC is not reliable for E. faecium by Vitek system. In vitro activity of penicillin and ampicillin versus E. faecium accurately predicts that of imipenem.
Agar
;
Ampicillin
;
Anti-Infective Agents
;
Coinfection
;
Enterococcus faecium*
;
Enterococcus*
;
Imipenem*
;
Microbial Sensitivity Tests
;
Penicillins
9.Prevalence of Carbapenemase and Integrase Genes in Imipenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa Collected over Several Years in a University Hospital.
Hye Ryong OH ; Sook Jin JANG ; Feng Nan YU ; Geon PARK ; Xue Min LI ; Sung Heui SHIN ; Won Yong KIM ; Dae Soo MOON ; Young Jin PARK
Korean Journal of Clinical Microbiology 2007;10(2):128-134
BACKGROUND: The incidence of infections with imipenem- resistant Acinetobacter baumannii (IRAB) and Pseudomonas aeruginosa (IRPA) is increasing worldwide, and recent molecular studies indicate that the prevalence of carbapenemases is increasing in various parts of the world. However, few long-term longitudinal studies have assessed the prevalence of IRAB- and IRPA-derived carbapenemases and integrases in a hospital setting in Korea. METHODS: The carbapenemase genes (blaOXA-23, blaOXA-24, blaOXA-58, blaIMP-1, blaVIM-2, blaSIM-1, blaSPM-1) and integrase genes (intI1, intI2, intI3) produced by 46 IRAB strains and 51 IRPA strains collected at Chosun University Hospital between 2003 and 2006 were determined by PCR. RESULTS: The IRAB strains produced class 1 integrases more often than did the IRPA strains. However, the incidence increased steadily in both strains, reaching 100% in 2006. Carbapenemases of blaIMP-1 and blaVIM-2 types were found in 57% and 64% of the IRAB strains, respectively, in 2003. However, only one strain with blaVIM-2 was found in 2004 and another one with blaIMP-1 in 2005. The prevalence of carbapenemases was very low in the IRPA strains, just one strain with blaVIM-2 in 2005 and another one with blaoxa-23 in 2006. No other types of carbapenemase genes were detected in both strains. Rep-PCR of IRAB strains in 2003 showed different patterns. CONCLUSION: The incidence of carbapenemase varied by year but was generally low, except in 2003. The prevalence of class 1 integrases was consistently high and increased every year. The reason for the high prevalence of carbapenemases in 2003 is still unknown, but we assumed that it was not from the spread of a clone containing either blaIMP-1 or blaVIM-2 because the strains exhibited different rep-PCR patterns.
Acinetobacter baumannii*
;
Acinetobacter*
;
Clone Cells
;
Imipenem
;
Incidence
;
Integrases*
;
Korea
;
Polymerase Chain Reaction
;
Prevalence*
;
Pseudomonas aeruginosa*
;
Pseudomonas*
10.Emergence of Acinetobacter pittii Harboring New Delhi Metallo-beta-Lactamase Genes in Daejeon, Korea.
Ji Youn SUNG ; Sun Hoe KOO ; Semi KIM ; Gye Cheol KWON
Annals of Laboratory Medicine 2015;35(5):531-534
Carbapenemase production has been reported worldwide in gram-negative bacteria, including Acinetobacter species. We detected carbapenemase-producing Acinetobacter pittii in clinical isolates in Daejeon, Korea. Twenty-one ertapenem-resistant A. pittii isolates screened with a disk diffusion method were characterized by using the Epsilon test, four multiplex PCR assays, and a multilocus sequence typing (MLST) scheme. A total of 21 A. pittii isolates harbored the metallo-beta-lactamase (MBL) gene bla(IMP-1) or bla(NDM-1). Nineteen isolates containing bla(IMP-1) were resistant to imipenem and meropenem, but two isolates harboring bla(NDM-1) were susceptible to them. The sequence types (STs) of the two New Delhi MBL (NDM-1)-producing A. pittii isolates were ST70 and ST207, which differed from the STs (ST63, ST119, ST396, and a novel ST) of the IMP-1-producing A. pittii. This is the first report on NDM-1-producing A. pittii isolates in Korea. Our results emphasize that the study of NDM-1-producing gram-negative bacteria should involve carbapenem-susceptible as well as carbapenem-resistant isolates.
Acinetobacter*
;
Diffusion
;
Gram-Negative Bacteria
;
Imipenem
;
Korea
;
Multilocus Sequence Typing
;
Multiplex Polymerase Chain Reaction